- Report
- October 2022
- 120 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Drug Pipelines
- January 2019
- 163 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Drug Pipelines
- October 2020
- 773 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- September 2020
- 40 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- September 2020
- 385 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- September 2020
- 35 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- August 2020
- 39 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- August 2020
- 56 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- August 2022
- 580 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- May 2022
- 40 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- May 2022
- 40 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- June 2021
- 40 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- June 2021
- 44 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- March 2021
Global
From €1930EUR$2,000USD£1,656GBP
- Drug Pipelines
- July 2020
- 128 Pages
Global
From €1930EUR$2,000USD£1,656GBP
- Report
- February 2024
- 201 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- February 2024
- 175 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- May 2023
- 160 Pages
Global
From €5790EUR$5,999USD£4,967GBP
Thrombolytics are a class of cardiovascular drugs used to treat acute ischemic stroke, myocardial infarction, and pulmonary embolism. They work by breaking down the clot that is blocking the blood vessel, allowing blood to flow freely. Thrombolytics are typically administered intravenously, and can be used in combination with other treatments such as anticoagulants and antiplatelet drugs. The most commonly used thrombolytic is tissue plasminogen activator (tPA), which is a recombinant form of the naturally occurring enzyme plasminogen.
The thrombolytics market is highly competitive, with a number of companies offering products for the treatment of cardiovascular diseases. Some of the major players in the market include Boehringer Ingelheim, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more